- PharmaMar is a biotech company world leader in the
discovery, development, and commercialization of marine-derived
cancer drugs.
- More than half of the patients, 52,7%, in a PharmaMar
study attained an objective response (tumour shrinkage of ≥30%)
from a combination treatment for Small Cell Lung Cancer with a
chemotherapy-free interval greater than 30 days responded to
treatment.
- The study was presented at the world's largest clinical
oncology congress held in Chicago,
USA between May 31st and June 4th.
MADRID, June 4, 2024
/PRNewswire/ -- PharmaMar (MSE: PHM), world
leader in the discovery, development and commercialization
of marine-derived cancer treatments, presented data
from a Phase II trial evaluating PharmaMar's lurbinectedin
in combination with irinotecan in patients with
relapsed Small Cell Lung Cancer (SCLC) after prior
platinum-based treatment at the American Society of Clinical
Oncology (ASCO) meeting, which took place from
31st May to 4th
June in Chicago,
United States.
PharmaMar has a unique technological platform: the sea. Since
1986, it has been researching the marine ecosystem to discover
innovative therapeutic alternatives for serious diseases, such as
cancer, for this purpose it has invested more than one billion euros since its foundation. After
reaching patients all over the world and changing the paradigm of
sarcoma treatment, in addition to having three therapies
commercially available, it is currently working to improve the
lives of patients with Small Cell Lung Cancer, the most aggressive
type of lung cancer.
Regarding this disease, the results presented by the company at
ASCO show that the combination of its drug for this pathology,
Zepzelca® (lurbinectedin), in combination with
irinotecan produces a synergy that enhances the activity of
lurbinectedin, resulting in high and durable response rates in
populations that are sensitive, with a chemotherapy-free interval
greater than 90 days (CTFI> 90 days), and platinum-resistant
with a chemotherapy-free interval of less than 90 days (CTF< 90
days).
Particularly encouraging are the data drawn from the subgroup of
74 patients with a chemotherapy-free interval greater than 30 days
(CTFI>30 days) with a response rate of 52.7% and a median
response duration of 7.6 months.
Among the study data within this subgroup, the overall survival
(OS) data is also encouraging, with a median of 12.7 months. The
safety profile has proven to be manageable with a low percentage of
treatment interruptions.
Zepzelca® (lurbinectedin) is a synthetic compound
derived from the tunicate Ecteinascidia turbinata found by
PharmaMar in the Caribbean Sea, the Gulf
of Mexico and the Mediterranean Sea. It is approved in 16
territories around the world. It received FDA accelerated approval
in 2020 and has become the standard of care for second-line
treatment in the United States.
Confirmatory trials are currently underway, which may eventually
lead to approval in Europe as
well.
One of the confirmatory studies, LAGOON, consists of three arms,
one of which is lurbinectedin with irinotecan. The results
presented at ASCO reinforce the rationale for including this
combination as an experimental arm with this type of patient in
this ongoing pivotal trial.
Legal warning
This press release does not constitute
an offer to sell or the solicitation of an offer to buy securities,
and shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction.
About PharmaMar
PharmaMar is a biopharmaceutical
company focused on the research and development of new oncology
treatments, whose mission is to improve the healthcare outcomes of
patients afflicted by serious diseases with our innovative
medicines. The Company is inspired by the sea, driven by science,
and motivated by patients with serious diseases to improve their
lives by delivering novel medicines to them. PharmaMar intends to
continue to be the world leader in marine medicinal discovery,
development and innovation.
PharmaMar has developed and now commercializes
Yondelis® in Europe by
itself, as well as Zepzelca® (lurbinectedin), in the US;
and Aplidin® (plitidepsin), in Australia, with different partners. In
addition, it has a pipeline of drug candidates and a robust R&D
oncology program. PharmaMar has other clinical-stage programs under
development for several types of solid cancers: lurbinectedin,
ecubectedin, PM534 and PM54. It also has a preclinical and clinical
program in virology. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in
Germany, France, Italy, Belgium, Austria, Switzerland and The
United States. PharmaMar also wholly owns Sylentis, a
company dedicated to researching therapeutic applications of gene
silencing (RNAi). To learn more about PharmaMar, please visit us at
www.pharmamar.com
PM1183-A-014-15
PM1183-A-014-15 is a multicenter,
open-label Phase I/II Basket study of lurbinectedin in combination
with irinotecan in relapsed first lines patients. The study
enrolled 101 patients in the SCLC cohort, and the results showed a
good outcome in this patient population, included in one arm of the
lurbinectedin plus irinotecan combination of the LAGOON study.
These results refer to the Overall Response Rate (ORR), Duration of
Response (DoR), Progression-Free and Overall Survival (PFS and OS),
along with a manageable safety and tolerability profile.
About Zepzelca®
Zepzelca® (lurbinectedin), also known as PM1183, is
an analog of the marine compound ET-736 isolated from the sea
squirt Ecteinascidia turbinata in which a hydrogen atom has
been replaced by a methoxy group. It is a selective inhibitor of
the oncogenic transcription programs on which many tumors are
particularly dependent. Together with its effect on cancer cells,
lurbinectedin inhibits oncogenic transcription in tumor-associated
macrophages, downregulating the production of cytokines that are
essential for the growth of the tumor. Transcriptional addiction is
an acknowledged target in those diseases, many of them lacking
other actionable targets.
Photo -
https://mma.prnewswire.com/media/2429110/PharmaMar_1.jpg
Logo -
https://mma.prnewswire.com/media/2429111/PharmaMar_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.co.uk/news-releases/pharmamar-presents-encouraging-results-at-asco-for-small-cell-lung-cancer-302162539.html